17-Jul-2020 - Sartorius AG

Sartorius raises forecast for the full year of 2020

Stronger growth and higher profitability expected for the Bioprocess Solutions Division and the entire Group

Based on the strong performance of the Bioprocess Solutions Division in the first half of 2020 as well as on high demand also expected to continue for the rest of the current fiscal year, Sartorius raised its full-year sales and earnings guidance for this division and thus for the entire Group. Management now expects consolidated sales revenue to increase by 22% to 26% (previously 15% to 19%) and the Group’s underlying EBITDA margin to reach around 28.5% (previously about 27.5%). Upward revision of this forecast is partly due to the current coronavirus pandemic as Sartorius products are used for manufacturing both vaccines and antiviral medications.

For the Bioprocess Solutions Division, management now forecasts sales growth of 26% to 30% (previously 17% to 21%) and an underlying EBITDA margin of approximately 31% (previously around 30%). The outlook for Lab Products & Services remains unchanged, with sales revenue expected to grow by 10% to 14% at an underlying EBITDA margin of approximately 20% (all forecasts are based on constant currencies as in the past).

Due to the ongoing pandemic, this guidance is subject to greater uncertainty than usual. In particular, these updated projections are based on the assumptions that logistics chains will continue to be stable and production lines remain in operation.

In the first half of 2020, the Sartorius Group increased its order intake according to preliminary figures by 27.5% in constant currencies. Its sales revenue rose by 17.9% at an underlying EBITDA margin of 27.8%.

More about Sartorius